PEPI-TiDP23-C103: First-in-Human Study to Examine the Safety, Tolerability, and Plasma Pharmacokinetics of Increasing Single and Repeated Oral Doses of TMC558445 and of a Combined Single Day Dosing of Oral TMC558445 and Oral TMC310911 and Also Oral Darunavir

Name: PEPI-TiDP23-C103: First-in-Human Study to Examine the Safety, Tolerability, and Plasma Pharmacokinetics of Increasing Single and Repeated Oral Doses of TMC558445 and of a Combined Single Day Dosing of Oral TMC558445 and Oral TMC310911 and Also Oral Darunavir
Published: 2009
License: Public Domain

Tibotec Pharmaceuticals, Ireland · 2009

ClinicalTrials.gov · Datasets · License: Public Domain · 2009

Open Source ↗

hiv-1 hiv-infections pharmacokinetics

hiv-1, pepi-tidp23-c103, pepi-c103, pepi, tmc558445, tmc310911, darunavir, healthy volunteers, pharmacokinetics, hiv infections, interventional, phase1

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

PEPI-TiDP23-C103: First-in-Human Study to Examine the Safety, Tolerability, and Plasma Pharmacokinetics of Increasing Single and Repeated Oral Doses of TMC558445 and of a Combined Single Day Dosing of Oral TMC558445 and Oral TMC310911 and Also Oral Darunavir

Related documents